Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 31 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M3\vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:0PEBp MVnJR|UxRTF|OT6yNQKBkcLz4pEJOU46PSEQvF2= MWeyOVk3ODJ6Mh?=
KellyCis83 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnifFc1QCCq MYDJR|UxRTJ3MT6wNQKBkcLz4pEJNVUvPzVizszN NFXNXnUzPTl4MEK4Ni=>
SK-N-AS NVfoPZF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTCOFghcA>? M2nHZ2lEPTB;MkK3Mlcx6oDLwsJihKkzOi5zNTFOwG0> Mnv3NlU6PjB{OEK=
SK-N-ASCis24 NVXHOW5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHXOFghcA>? NGLUfWpKSzVyPUS4NE43OOLCidMx5qCKOTBzLkG1JO69VQ>? NEL4VWIzPTl4MEK4Ni=>
CHP-212 M{K1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3PWmU1QCCq MXnJR|UxRTdwOUhihKnDueLCiUCuOlkh|ryP NFfLelkzPTl4MEK4Ni=>
CHP-212Cis100 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP4d4M1QCCq NX;kenBMUUN3ME25MlU26oDLwsJihKkxNjh6IN88US=> NXrDW5oxOjV7NkCyPFI>
U87  NU\HTJhMTnWwY4Tpc44hSXO|YYm= MUOxNFAh|ryP NFewPVIzPC15MjDo MlKzbY5lfWOnczDEZ3IyKGW6cILld5Nqd25? M3LRVVI2QDB6OE[4
LN229 M{DiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLtNE02OCEQvF2= NXHveG1OUUN3ME2xOkDPxE1? NFqzSnIzPTd3MEK3Ny=>
TR-LN229 M3v6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HCfVAuPTBizszN NFrVOlVKSzVyPUe3JO69VQ>? Ml7XNlU4PTB{N{O=
U87  NGDoZ|ZCeG:ydH;zbZMhSXO|YYm= MWqw5qCUOjBy4pEJxtVO MYqyOEBp MXHlcohidmOnczDDVUBqdmS3Y3XkJIFxd3C2b4Ppdy=> MVuyOVY5OTZ4OB?=
U251MG MV3BdI9xfG:|aYOgRZN{[Xl? NXzUR5Z1OTBywrFOwG0> M3TVe|Q5KGh? MmS5VGJU NUjFXlVLcW6mdXPld{BieG:ydH;zbZM> MmCwNlU3QDB2NkS=
U87MG MVjBdI9xfG:|aYOgRZN{[Xl? NHWx[JIyODEEoN88US=> NYXndY93PDhiaB?= NGr6XWRRSlN? MnnrbY5lfWOnczDhdI9xfG:|aYO= MVmyOVY5ODR4NB?=
U87 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLRVnp4PTBvM{WwJO69VQ>? MWm0POKhcMLi MoW5bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> MYeyOVU2PDJ{Mx?=
U118  MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nWPVUxNTN3MDFOwG0> Mni5OFjDqGkEoB?= NGXzc4RqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? MVuyOVU2PDJ{Mx?=
U87 MnHzSpVv[3Srb36gRZN{[Xl? Ml3nNlUxNzN3MDFOwG0> NGXGWGs1QMLiaNMg M4LVPYVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? Mk\zNlU2PTR{MkO=
U118  MUTGeY5kfGmxbjDBd5NigQ>? M4DIXlI2OC9|NUCg{txO NHrtbnM1QMLiaNMg M4rpbYVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? NFjSTHkzPTV3NEKyNy=>
U87 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LBUVI2OC9|NUCg{txO NFzZSZI1QMLiaNMg MmrZbY5kemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJHMh[W6mIFeyM23DqGOxdILlZZRm\CC5aYToJHROYA>? M1nJT|I2PTV2MkKz
A375 NHX0V2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojWOFjDqGkEoB?= M1;mUWlEPTB;Mk[1JO69VQ>? NI\FdnkzPTV{NEW1Ni=>
A2058 NVXsPGZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnkXohXPDkEoHlCpC=> NFyzOGFKSzVyPUGyJO69VQ>? NWHC[WVDOjV3MkS1OVI>
M238 NUnTS442T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr4W|h5PDkEoHlCpC=> NITIfm9KSzVyPUSwJO69VQ>? NUS1RldHOjV3MkS1OVI>
M249 NF;nc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXW0POKhcMLi MVXJR|UxRTJ3NDFOwG0> NUDrcGpUOjV3MkS1OVI>
M21 M{P5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnrXWhYPDkEoHlCpC=> MVfJR|UxRTJ{MTFOwG0> M2Xvc|I2PTJ2NUWy
U251 NWCxdGFoS3m2b4TvfIl1gSCDc4PhfS=> MkH2NlAh|ryPwrC= MW[0POKhcMLi M2mzVpJm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS= NF\RVGUzPTR|NEO4NS=>
LN229 MlrLR5l1d3SxeHn0fUBCe3OjeR?= NYDWeW1LOjBizszNxsA> NHW0OJY1QMLiaNMg MV\y[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm MVuyOVQ{PDN6MR?=
U373MG-LUC M1vwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUC3NkBp Mk[0TWM2OD54MECg{txO NUfyOJVnOjV2M{G5OVM>
U87  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W1TFI2NTJyMDFOwG0> NXHpU4NzPDkEoHlCpC=> NUfnblV5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWTCdGZiOjV2MEC3OFU>
U251 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTvdJkzPS1{MECg{txO M4rzRlQ5yqCqwrC= NF3KN|dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{TZNFI2PDByN{S1
U251 NWfjbWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm0[mtUOTByLUSwNEDPxE1? MXS3Nk86PiCq M33uOZRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= NF;DXJUzPTN5NUK3NS=>
U373 NGjFT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLwNVAxNTRyMDFOwG0> M{fQ[VczNzl4IHi= MoPmeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi M2PrWlI2Ozd3Mkex
U343 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC0NYxSOTByLUSwNEDPxE1? NWn2Z4NYPzJxOU[gbC=> M4flfpRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MVGyOVM4PTJ5MR?=
U87MG-luc2 M4nrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXGNVAxNTRyMDFOwG0> NFzhdY44Oi97NjDo NF;a[5Z1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= MVqyOVM4PTJ5MR?=
U87 MmnzSpVv[3Srb36gRZN{[Xl? NUfRUIRjOjByIN88US=> NEfWTog1QCCq NYDBTYp5cW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= MnrYNlU{Ozd5MkG=
U251 Mn2ySpVv[3Srb36gRZN{[Xl? NVvFWlZuOjByIN88US=> M1XqXVQ5KGh? M1vScIlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? NEHvRoIzPTN|N{eyNS=>
A172 MlfvSpVv[3Srb36gRZN{[Xl? MoX0NlAxKM7:TR?= MmrkOFghcA>? MoHubY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? NVLDW|dEOjV|M{e3NlE>
U251 Mn;xSpVv[3Srb36gRZN{[Xl? MlT1NlAxKM7:TR?= M3[4clQ5KGh? NGL5fnZqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{ NFHmbVYzPTN|N{eyNS=>
A172 NULCdZdITnWwY4Tpc44hSXO|YYm= M4DJVlIxOCEQvF2= M3rDT|Q5KGh? MkjObY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MmDTNlU{Ozd5MkG=
U87 NGX2VGJHfW6ldHnvckBCe3OjeR?= NHvxVYYzODBizszN M2XBNVI1Nzd{L{GyNEBp NXrBcXBUcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 M{\4d|I2OzN5N{Kx
U251 NWS1dJVkTnWwY4Tpc44hSXO|YYm= Mn7nNlAxKM7:TR?= MXKyOE84Oi9zMkCgbC=> NWXEN2RUcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 M4q0VVI2OzN5N{Kx
A172 MWXGeY5kfGmxbjDBd5NigQ>? M3foW|IxOCEQvF2= NIrlNGkzPC95Mj:xNlAhcA>? NGn5VXRqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? M3jzNVI2OzN5N{Kx
SNB19V NH7INZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLYWYFHPyCm NYLRd4poTE2VTx?= MmfoS2k2OD1|NT63xtEyOiEQvF2= NFjSPZMzPTJ5N{S0NS=>
SNB19M MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT5[XpLPyCm MYHEUXNQ MnjjS2k2OD12NkmuPeKyQDhizszN MV:yOVI4PzR2MR?=
SNB19VR MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y4dlch\A>? NXvIR|hlTE2VTx?= MUHHTVUxRTJ6MD6yxtEyQCEQvF2= NFTX[GEzPTJ5N{S0NS=>
U373V M3zNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7PUZZIPyCm MWrEUXNQ NIP6VXRIUTVyPU[4MlDDuTN{IN88US=> NVL6WVNvOjV{N{e0OFE>
U373M MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfOO{Bl NEDjOmlFVVOR NV7vdY5zT0l3ME2zOlgvP8LzOE[g{txO NE\veWszPTJ5N{S0NS=>
U373VR NFXFWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK4Vm1zPyCm NGLJTpVFVVOR M1nVUmdKPTB;Mki4MljDuTN|IN88US=> M4XsOFI2Ojd5NESx
U87MG MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVm3JIQ> NITFU3lFVVOR MkHnS2k2OD1|OD6zxtEzOCEQvF2= NWXTPGN5OjV{N{e0OFE>
HCT116 NH;YNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjPe5ZJPyCm NYfvb5V4TE2VTx?= NXjxT3JzT0l3ME21O|kvQcLzM{Kg{txO NILLZ|UzPTJ5N{S0NS=>
DLD1 NWnieVJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLUO{Bl NEfZdphFVVOR MWHHTVUxRTVyMT60xtE6OyEQvF2= MkKwNlUzPzd2NEG=
MRC5 MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f0RVch\A>? NUHNXYxxTE2VTx?= M4H6dGdKPTB;NES5MlTDuThizszN NHm5fGMzPTJ5N{S0NS=>
SNB19V  M2PKfWZ2dmO2aX;uJGF{e2G7 NWfE[nBGOTByIN88UeKhXE2c Mo\mNE04OiCq MYLpcoNz\WG|ZYOg{tNJOkG[IHX4dJJme3Orb36gZoV1f2WnbjCxOkBidmRiN{KgbC=> MlXqNlUzPzd2NEG=
T98G  NHraZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljHOU8yOC9zNTFOwG0> NFPkfHAzPMLiaB?= MlXDbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= NHrObYIzPTJ4Mkm2NS=>
U251  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPlflNMPS9zMD:xOUDPxE1? M3\vVlI1yqCq NUjLd3c4cW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wt[IVx\W6mZX70cJkh[W[2ZYKgZ49v[2:vaYThcpQufGWvb4rvcI9ucWSnIIfpeIghVlCnNj3QSHQ> MkmyNlUzPjJ7NkG=
T98G  NXXuT4pSTnWwY4Tpc44hSXO|YYm= NFPHN48yPSEQvF2= NIDDOIEzPMLiaB?= MWfpcoNz\WG|ZYOgSG5CNW[{YXft[Y51[XSrb36gbY4hVlCnNj3QSHQhfHKnYYTl[EBodGmxbXGgZ4VtdHN? MVeyOVI3Ojl4MR?=
U251  MnPISpVv[3Srb36gRZN{[Xl? NVvMdo56OTVizszN MlrGNlTDqGh? NWTWc4tWcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz MYiyOVI3Ojl4MR?=
U-87 MG NW\JV2RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXmU3JvPzJiaB?= NXnhOI1jUUN3ME2wMlk{KG2PwrC= MoiyNlUzPDV|M{K=
U-118 MG MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS3fI44OiCq M4nWbGlEPTB;MT6wOUBuVcLi MVKyOVI1PTN|Mh?=
U87 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LJZVI1KGh? M4n4emlEPTB;Mk[wMlM1KM7:TdMg NHvUeYMzPTF5M{KzNy=>
U87 GSLCs M2DVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTzOZNyOjRiaB?= M{DpUGlEPTB;N{[2MlEyKM7:TdMg NXH3dIJPOjVzN{OyN|M>
U87MG M2TKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PaWFczKGh? NHy1SJJKSzVyPUG1MlYzPSEQvF5CpC=> NUD3bXlzOjVyNUC5NVU>
U251 M{Twcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXPeoIyODBvNECwJO69VQ>? M2DOTVQ5KGh? M2PDWmROW09? NETzNmRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2K4PVI1PjJ|N{O2
U87 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O0VVExOC12MECg{txO M4rhTlQ5KGh? NF3DUotFVVOR MmP0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXKyOFYzOzd|Nh?=
MDA-MB-231-br NIHpT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzTWHcxNTFyIN88US=> MUG0PEBp NF\vfIFFVVOR MkHKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVrOS2k5OjR4MkO3N|Y>
HCC-1937 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWwMVMxOCEQvF2= M3TkPVQ5KGh? MVLEUXNQ Mn;4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFX4bpMzPDZ{M{ezOi=>
MDA-MB-231 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH23TVMxNTRyIN88US=> M{nCdlQ5KGh? NWfhOpdXTE2VTx?= MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MV2yOFYzOzd|Nh?=
MDA-MB-468 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiwMVUxOCEQvF2= MX:0PEBp NUf4[oRoTE2VTx?= MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF;PW5gzPDZ{M{ezOi=>
T47D M4\VNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SzT|AuOTByIN88US=> MYi0PEBp M2nPRWROW09? Mlv6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1TIclI1PjJ|N{O2
MCF7 MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOzOIIxNTFyMECg{txO NF6xcnU1QCCq M4XTeWROW09? NV\IN4QxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXSyOFYzOzd|Nh?=
Hs683 M4HOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCwMVExODBizszN Ml71PVYhcA>? M{TUeGlEPTB;MUK4Mlkh|ryP MlTTNlQ1QTV7MEe=
U87 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqwMVExODBizszN MXm5OkBp NGLNNoVKSzVyPUG4MlQ2KM7:TR?= NIjVSnMzPDR7NUmwOy=>
LNZ308 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnodmRMOC1zMECwJO69VQ>? MVS5OkBp NHXnfJlKSzVyPUOyOk44KM7:TR?= NX3UeHR3OjR2OUW5NFc>
U87 M4e3PWFxd3C2b4Ppd{BCe3OjeR?= NH\B[WsyODBizszN MVu0PEBp NUO1RmhQTE2VTx?= Mn3VbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= NX7iRWkyOjR2OEG1PFY>
U251  M{nJTGFxd3C2b4Ppd{BCe3OjeR?= MX2xNFAh|ryP MWO0PEBp NVnIZ5VmTE2VTx?= NXvjWXVxcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> NE\0VHUzPDR6MUW4Oi=>
U251 M13HWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\6dFI1KGh? MkLNTWM2OD16Nj6yPgKBkcLz4pEJNU42QCEQvF2= MYqyOFMzPjl3NB?=
U251 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jkUFQ5KGh? M3zXOmlEPTB;N{WuN|TjiIoEsfMAjVEvODJizszN MWSyOFMzPjl3NB?=
U251 M3nHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWC3NkBp NEe0O41KSzVyPUeyMlQz6oDLwsJihKkyNjR3IN88US=> MmT1NlQ{OjZ7NUS=
U251 NWryNXI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:5OkBp M1T0e2lEPTB;NkmuPFLjiIoEsfMAjVMvODRizszN MnnzNlQ{OjZ7NUS=
T98G M{PwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS0NE04PTBizszN MWq3Nk86PiCq Mn7mbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXrSVnl5OjR|MkSwPFA>
U251-MG MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSwMVgxOCEQvF2= MYq3NkBp M2rDS4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWKyOFA6OzZ|MB?=
D54-MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMVgxOCEQvF2= NIDFT4k4OiCq MXLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NXfIeJNPOjRyOUO2N|A>
SHG-44 NX:0ZlNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TFeFExNTJyMDFOwG0> NIPBbGg6PiCq MlLuTWM2OD17LkezJOKyKDJwMUKg{txO NF;tXoszPDB4NUW2PS=>
U373  NFPpV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHhS|AyOC1{MECg{txO MX:5OkBp MXnJR|UxRTFyLkGzJOKyKDFwMEKg{txO NF;GXo0zPDB4NUW2PS=>
HT-29  M3e2dWZ2dmO2aX;uJGF{e2G7 MoXOOVAxKM7:TR?= NXn5ZpNXOjRxNEigbC=> M1nzOIVvcGGwY3XzJJRp\SCuZY\lcJMhd2ZizsOtTFJCYMLi MVuyOFA{QDB4OB?=
PC-3  NXz1U5h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWewMVI2KM7:TR?= M{XxSlQ5KGh? MV\pcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> M3Lte|I{PzR4OUO0
PC-3  M3y1OGFxd3C2b4Ppd{BCe3OjeR?= M135WlI2KM7:TR?= NVnFcYRsPDhiaB?= NF7JXXFqdmS3Y3XzJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> MlTENlM4PDZ7M{S=
T98G NYe4PXhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK1NE01ODBizszN MU[xOFQhcA>? Ml3TbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXvYeG57OjN5MUW0PVk>
U87-MG NXfTRWdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW3NVAxKML3TR?= M{Xnb|czKGh? NXLyUohKcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= NYDp[HpOOjN4OU[3PFg>
U251-MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLTTJcxOTByINM1US=> MX:3NkBp NFLwbHhqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE NVHDe|lxOjN4OU[3PFg>
LNT-229 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS2Rlk{NTFyMDFOwG0> NV;Gd3IxOjRiaB?= NVjVVGxvcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIDRW2kzOzZ4N{[zNi=>
T98G M1fz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNE04ODBizszN NEHyNVAzPCCq NUDybnJpcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoLnNlM3Pjd4M{K=
U87  NHi5b5ZHfW6ldHnvckBCe3OjeR?= M2TnNVExOCEEtV2= MnuxN{Bp NUTRNGp1\WyndnH0[ZMhfGinIHzleoVteyCxZjDwR4hsOSCjbnSgdGNpczJ? NX;2TGw6OjN4Nke0Olk>
HCT116 M2S4S2Z2dmO2aX;uJGF{e2G7 NFrzfIwyODBiwsXN NF7ZdXI{KGh? NH\QZllqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= MkHONlM3Pjd2Nkm=
HCT3-6 MkSwSpVv[3Srb36gRZN{[Xl? MoDKNVAxKML3TR?= Ml30N{Bp NEHhfWlqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= NGfIfHUzOzZ4N{S2PS=>
U-87  MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGwMVQxKM7:TR?= M1TpZVEzKGR? MnvzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3;RclI{PjR3N{K5
U-87  NUXmcmdoSXCxcITvd4l{KEG|c3H5 NWDYbVF5OC12MDFOwG0> M2\2RlMwPiCm M1T3colv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NF32eJozOzZ2NUeyPS=>
U-87  MXHGeY5kfGmxbjDBd5NigQ>? MmjlNE01OCEQvF2= NHvke2s{NzZiZB?= MXHpcoR2[2W|IHH1eI9xcGGpeTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MXuyN|Y1PTd{OR?=
GB-SCC010 NEXYdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom4OEBl M3qweWlEPTB;MkK2JO69VQ>? M{LyTFI{PjF{N{W1
GB-SCC026 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3mOEBl MkPJTWM2OD13Mz6xJO69VQ>? NYLTd|FbOjN4MUK3OVU>
GB-SCC028 NX7EVlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD3TFVmPCCm M4Tl[WlEPTB;MU[3JO69VQ>? NFrXZpozOzZzMke1OS=>
U87 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfYOEBl MWLJR|UxRTR3LkKg{txO MkjBNlM3OTJ5NUW=
U87 stem cell MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTpOEBl MVzJR|UxRTZ4Lkeg{txO MkP0NlM3OTJ5NUW=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]
- Collapse
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]
- Collapse
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2
CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04091503 Not yet recruiting Drug: Intranasal Modified Temozolomide Glioma Malignant|Gliosarcoma|Astrocytoma of Brain Center Trials & Treatment Europe December 10 2019 Phase 1
NCT03796507 Not yet recruiting Drug: Temozolomide Glioma of Brain University of Rochester|National Institutes of Health (NIH) November 1 2019 Early Phase 1
NCT03932981 Recruiting Drug: Temozolomide Adult Brainstem Glioma Assistance Publique - Hôpitaux de Paris July 26 2019 Phase 2
NCT03709680 Recruiting Drug: Palbociclib|Drug: Temozolomide|Drug: Irinotecan Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma Pfizer May 24 2019 Phase 1
NCT03832621 Recruiting Drug: Temozolomide|Drug: Nivolumab|Drug: Ipilimumab Metastatic Colorectal Cancer Fondazione IRCCS Istituto Nazionale dei Tumori Milano March 25 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

  • SCR7 New

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.

  • Blasticidin S HCl New

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279 New

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. DMF is recommended, compared with DMSO.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Gemcitabine

    Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Carboplatin

    Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

    Features:A DNA synthesis inhibitor.

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID